Pacific Edge Limited (PFGTF) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pacific Edge Limited reported a modest decrease in Q2 FY25 Cxbladder test volumes compared to the previous quarter, attributing the dip to uncertainties over Medicare coverage. Despite this, the company saw strong demand from Kaiser Permanente and increased test volumes in the Asia Pacific region, mitigating the overall impact. The company remains focused on strategic initiatives aimed at enhancing clinical practice and medical reimbursement policies, which are expected to contribute to future growth.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue